Guangzhou Headquarters and R&D Center, China
25/01/2016
Global Facilities
Proteins: mAb, bsAb, fusion protein and recombinant protein from E. coli & CHO;
ATMP: Oncolytic Viruses (CAR-T, LBPs, etc.), Exosomes
CHO cell titer achieved 39 g/L in IFB;
Difficult to express protein platforms to tackle issues with tough protein expression.
Operated in full compliance with FDA, EMA, and NMPA quality standards;
Successfully passed over 50 domestic and international client audits;
From DNA to IND in 9 months (fast track), biosimilar usually 24-26 months
Enabled IND submissions for 30+ global clients.
3 core sites in China and 1 site in Germany, creating business flexibilities and allow QP release in EU;
100+ global customers;
Cost effective service modules: less than 50% cost of EU peers
Client Feedback
